Investigational drug · Phase 3
V116
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Pneumococcal Infection.
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
11
Any phase or sponsor naming "V116"
First trial start
2024
Jan 18, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "V116", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pneumococcal Infection
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "V116" as an intervention, largest first.
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05425732 · 2,663 participants · Start Jul 13, 2022 · Primary completion May 18, 2023
Drug: V116; PCV20 · For: Pneumococcal Infection
Sites: Birmingham, Alabama; Glendale, Arizona; Mesa, Arizona · 112 sites in all
- A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05464420 · 2,162 participants · Start Aug 12, 2022 · Primary completion May 25, 2023
Drug: V116; PPSV23 · For: Pneumococcal Disease
Sites: Mesa, Arizona; Tempe, Arizona; Little Rock, Arkansas · 72 sites in all
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05569954 · 1,484 participants · Start Nov 7, 2022 · Primary completion Oct 30, 2023
Drug: V116; PPSV23 · For: Pneumococcal Disease
Sites: Rosario, Argentina; Blacktown, Australia; Brookvale, Australia · 55 sites in all
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05526716 · 1,080 participants · Start Sep 23, 2022 · Primary completion Jun 21, 2023
Drug: V116; QIV and 1 more · For: Pneumonia, Pneumococcal
Sites: Phoenix, Arizona; Canoga Park, California; La Mesa, California · 56 sites in all
- A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06177912 · 882 participants · Start Jan 18, 2024 · Primary completion Feb 26, 2025
Drug: V116; PPSV23 · For: Pneumococcal Infection
Sites: Birmingham, Alabama; Phoenix, Arizona; Madera, California · 92 sites in all
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05420961 · 717 participants · Start Jul 12, 2022 · Primary completion May 16, 2023
Drug: V116; PCV15 and 1 more · For: Pneumonia, Pneumococcal
Sites: Birmingham, Alabama; Glendale, Arizona; Tempe, Arizona · 51 sites in all
- A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04168190 · 600 participants · Start Dec 6, 2019 · Primary completion Jul 12, 2021
Drug: V116; Pneumovax™23 · For: Pneumonia, Pneumococcal
Sites: Birmingham, Alabama; Mesa, Arizona; Coral Gables, Florida · 20 sites in all
- Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05696080 · 518 participants · Start Feb 13, 2023 · Primary completion Feb 16, 2024
Drug: V116; Placebo and 2 more · For: Pneumococcal Infection
Sites: Mesa, Arizona; Hialeah, Florida; West Palm Beach, Florida · 44 sites in all
- Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05633992 · 450 participants · Start Jan 10, 2023 · Primary completion May 24, 2023
Drug: V116; PPSV23 · For: Pneumococcal Disease
Sites: Osaka, Japan; Suita-shi, Japan; Hachiōji, Japan · 8 sites in all
- Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05393037 · 313 participants · Start Jul 13, 2022 · Primary completion Jul 13, 2023
Drug: V116; Placebo and 3 more · For: Pneumococcal Disease
Sites: Phoenix, Arizona; Washington D.C., District of Columbia; Ft. Pierce, Florida · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Projected epidemiological impact of lowering the adult pneumococcal vaccination age from 60 to 50 years in Germany.
Sharomi O, de Lepper M, Lang LM, et al. · Hum Vaccin Immunother 2026
- A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
Jagannath V, Pathirana J, Perez Yepes CA, et al. · Hum Vaccin Immunother 2026
- Invasive Pneumococcal Disease burden, clinical characteristics, serotypes' distribution, immunization status and antimicrobial resistance: Evidence from 12-year hospital-based surveillance and cost analysis.
Vecchio R, Iskandar E, Gentile L, et al. · Hum Vaccin Immunother 2026
- Epidemiological impact of a 20- or 21-valent pneumococcal conjugate vaccine in the Japan adult population: insights from a dynamic transmission model.
Oidtman RJ, Tajima A, Matsuki T, et al. · Expert Rev Vaccines 2026
- 21ߛValent Pneumococcal Conjugate Vaccine V116 (CAPVAXIVE®): Pediatric First Approval.
Shirley M · Paediatr Drugs 2026
- Heterodimerization with signaling-inert TLR8b converts TLR8a from proviral to antiviral sensor in Ctenopharyngodon idella.
Zhang J, Lv M, Wang S, et al. · Cell Commun Signal 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.